Peripheral arterial disease (PAD) is associated with an increased risk of overall cardiovascular mortality, and substantial morbidity resulting from claudication. While the initial disease process is clearly the result of atherosclerosis in the arterial circulation of the limb, altered hemodynamics do not completely explain the pathophysiology of claudication. Work from several laboratories has demonstrated secondary changes in the skeletal muscle of patients with PAD which are consistent with the presence of an acquired metabolic myopathy in these patients. Key findings include an alteration in the expression of mitochondrial enzymes, the accumulation of metabolic intermediates, altered regulation of mitochondrial respiration, increased oxidative stress, and the presence of somatic mutations in the mitochondrial genome. Understanding the metabolic changes associated with PAD is important in understanding the pathophysiology of claudication and in the development of novel therapeutic strategies.
Introduction
Peripheral arterial disease (PAD) results from atherosclerotic occlusion of arteries of the lower extremity. The prevalence of PAD increases with aging, exceeding 20% in the eighth decade. 1, 2 A diagnosis of PAD, including in asymptomatic individuals, is important in risk stratification due to the up to sixfold increase in overall cardiovascular mortality associated with PAD. 3 Approximately 40% of patients with PAD will suffer exercise-induced limb pain, or claudication. Claudication is associated with significant functional disability and impairment of quality of life. Claudication typically limits maximal walking capacity to approximately 50% of that in age-matched controls. 4 This results in the inability to perform a variety of occupational and recreational physical activities.
Despite the clear role of decreased arterial flow in claudication, hemodynamic limitations in the limb are poor predictors of the degree of claudication-associated impairment. 5, 6 Invasive revascularization does not completely normalize exercise performance, 7 and interventions such as exercise rehabilitation (which do not alter hemodynamics) have established efficacy. 8 These observations suggest that factors distal to the arterial obstruction may contribute to the pathophysiology of claudication.
The current review summarizes the evidence that PAD is associated with a skeletal muscle metabolic myopathy. Understanding the metabolic changes associated with PAD may lead to novel therapeutic strategies to minimize the functional impairment associated with claudication.
Skeletal muscle metabolic alterations in PAD
Alterations in mitochondrial expression in PAD Mitochondria are the cellular site of oxidative energy production, and thus play a key role in muscle bioenergetics. Muscle mitochondrial content can be assessed by the measurement of muscle mitochondrial enzyme activity. 9, 10 Muscle mitochondrial content is dynamic and increases or decreases to meet the metabolic demands of the tissue. 10 Thus, exercise training is associated with an increase in muscle mitochondrial content. 10 This increase in mitochondrial content correlates with the increase in oxidative exercise capacity. 11, 12 Similarly, detraining or sedentary behaviors are associated with a decrease in muscle mitochondrial content. 13 Over a wide range of total mitochondrial content, the ratio of individual mitochondrial enzyme activities remains invariant, reflecting the integrated structure of the organelle. 14, 15 Peripheral arterial disease leads to a limitation in physical activity, and an increasingly sedentary lifestyle. This level of physical activity might be considered analogous to detraining, and thus would be predicted to be associated with a decrease in mitochondrial enzyme activities. In contrast with this hypothesis, work from several laboratories has identified an increased mitochondrial content in the muscle of patients with PAD. [16] [17] [18] [19] This increased mitochondrial expression appears to be a direct consequence of, and is proportionate to, the severity of the occlusive disease. For example, bilateral gastrocnemius biopsies from patients with occlusive disease primarily in one leg demonstrate increased enzyme activities in the limb with significant hemodynamic changes when compared with the less-affected limb. 17 While PAD is associated with increased mitochondrial content, the regulation of mitochondrial enzyme activity may also differ from that in control subjects. Exercise training is a strong stimulus for mitochondrial proliferation in normal subjects. However, exercise training in patients with PAD has not been uniformly associated with enhanced mitochondrial activity. Some studies have documented increased mitochondrial enzyme activities with training in PAD, 18, 20 with others showing no increase despite achieving a systemic training response. 19 This suggests that the regulation of mitochondrial expression in PAD may be under a different series of control factors compared with normal subjects.
Mitochondrial enzymes are derived from both nuclear and mitochondrial DNA coding sequences. 21 While under most conditions there is coordinated regulation of the nuclear and mitochondrial genomes, 22 mitochondrial diseases, particularly abnormalities of the mitochondrial DNA (mtDNA), may lead to relatively enhanced nuclear versus mitochondrial expression. 23 Peripheral arterial disease is associated with increased ratios of citrate synthase (nuclear encoded) to cytochrome oxidase (mitochondrially encoded) activities. 24 This differential expression provides further evidence of altered mitochondrial expression in PAD. Further, muscle mtDNA content is higher in PAD than would be predicted based on the claudication limited exercise capacity. 25 The significance of altered mitochondrial expression in PAD is unclear. It has been hypothesized that increased mitochondrial content might improve oxygen extraction under ischemic conditions. 17 Additionally, if the regulation of the mitochondrial respiration is abnormal in PAD (see below), an increased mitochondrial content would allow each organelle to operate at a lower fraction of maximal capacity to yield the same oxidative ATP production in the tissue. Operation at this lower set point might allow compensation for any intrinsic abnormality in mitochondrial function. Similarly, the lower set point would minimize anaerobic metabolism and accumulation of intermediates of oxidative metabolism. 17
Accumulation of metabolic intermediates
Optimal oxidative efficiency occurs when fuel substrates are completely oxidized to CO 2 and water. Peripheral arterial disease is associated with the accumulation of metabolic intermediates that appear to reflect functionally important changes in metabolic function.
A number of key catabolic pathways utilize coenzyme A as an important cofactor. Fuel substrates are linked to coenzyme A, and through a series of reactions are further degraded, generating a sequence of coenzyme A derivatives. These coenzyme A-coupled intermediates, or acyl-CoAs, are linked to the cellular carnitine pool through the reversible transfer of acyl groups between carnitine and coenzyme A. 26 Carnitine and acylcarnitine concentrations are easily measured and provide a window into the metabolic state of the tissue. 27, 28 Peripheral arterial disease is associated with the accumulation of acylcarnitines in both plasma and skeletal muscle. 4, 28 This accumulation of acylcarnitines implies that acyl-CoAs are not being efficiently oxidized in the cells because the acyl-CoAs and acylcarnitine pools are in equilibrium. Importantly, the resting muscle acylcarnitine content is strongly and inversely correlated to the claudicationlimited exercise capacity in patients with PAD. 29 This functional correlation with a metabolic intermediate is in sharp contrast with the weak correlation between exercise Vascular Medicine 2000; 5: 55-59 performance and hemodynamics as assessed by the ankle/brachial index or calf blood flow. 5, 6 The effects of exercise rehabilitation further support the close link between metabolic changes and exercise capacity. Exercise training is effective in improving claudication-limited exercise performance in patients with PAD, with an increase in the peak walking times and peak VO 2 . 8 Additionally, exercise training is associated with a decrease in both plasma and muscle acylcarnitine content that is correlated with the degree of training-induced exercise improvement. 8, 19 In contrast, training does not affect lower extremity large vessel hemodynamics. 8, 30 Exercise training also improves lower extremity oxygen extraction in PAD, consistent with improved muscle metabolic status. 30 Taken together, these observations suggest that training has effects on skeletal muscle metabolism which are important in the beneficial response to the intervention.
In addition to the changes in the carnitine-acylcarnitine pool observed at rest, acylcarnitine accumulation in response to exercise is also abnormal in PAD. Acylcarnitine accumulation is seen at low workloads not associated with acylcarnitine accretion in normal subjects. 4, 29 Exercise is also associated with an accelerated accumulation of muscle lactate, 29 a product of the incomplete oxidation of glucose. Thus, PAD is associated with the accumulation of metabolic intermediates. This accumulation appears to be of functional importance due to the correlation of altered muscle metabolism with functional capacity in these patients.
Altered control of mitochondrial respiration in peripheral arterial disease
As discussed above, mitochondria couple the generation of reducing equivalents from the metabolism of fuels to the generation of ATP through the reduction of molecular oxygen to water. The control of mitochondrial respiration is complex. 31 However, changes in respiration in response to changes in energy demand can be quantified, and descriptive parameters used to compare metabolic regulation under different conditions. Kemp and colleagues have utilized 31 P-MRS to evaluate the control of respiration in the muscle of control subjects and patients with PAD. 32 Using the muscle ADP concentration as a marker of the driving force for mitochondrial respiration, mitochondrial function in PAD was characterized by an increased K m for ADP and decreased V max for oxidation. An apparent increase in K m is unusual in human chronic diseases, but is characteristic of classical mitochondrial myopathies. 32 These regulatory changes are also surprising in the context of the increased mitochondrial enzyme activities in PAD discussed above.
The control of cellular respiration can also be assessed by measuring the kinetics of ventilatory oxygen consumption. 33 In response to a change in workload, whole-body oxygen consumption approaches a new steady state with characteristic kinetics. In PAD, oxygen uptake kinetics are slowed when compared with age-matched sedentary controls (Figure 1 34 ). While changes in ventilatory oxygen kinetics cannot differentiate between central and peripheral limitations, when combined with the work of Kemp et al 32 these observations suggest that mitochondrial function is intrinsically impaired in patients with PAD. Figure 1 Oxygen uptake kinetics in PAD. Rates of oxygen uptake were measured as described 34 in a control subject (upper panel) and a patient with PAD (lower panel). Subjects underwent a transition from rest to walking exercise (2.0 mph, 4% grade) at time zero. The transition from rest to exercise is marked by a rapid increase in oxygen consumption to an early plateau at A 0 with a time constant t 0 . After a time delay, TD, the rate of oxygen uptake approaches the ultimate steady state (A 1 ) with time constant t 1 . Note the slower approach to steady state in the PAD subject. Reprinted from ref. 34 with permission from The American Physiological Society.
PAD is associated with enhanced oxidative stress
Work in a number of model systems, particularly the heart, has demonstrated that ischemia, and ischemia-reperfusion, are associated with marked oxidative stress due to the production of free radicals. 35, 36 Additionally, the atherosclerotic process itself and associated ischemia may generate oxidative stress due to the enhanced activation of circulating neutrophils. 37 Both of these lines of reasoning suggest that PAD would be associated with enhanced oxidative stress.
Several investigators have used a variety of approaches to characterize the oxidative stress in patients with PAD. [38] [39] [40] Malondialdehyde is a marker of lipid peroxidation in response to free radical generation. Malondialdehyde concentrations are markedly elevated in PAD, and increase further with exercise. 38, 39 Additionally, circulating neutrophils from patients with PAD are activated, 40 providing an additional source of systemic oxidative stress.
Oxidative stress may be important from a metabolic perspective in several ways. First, increased free radical production may be a consequence of impaired mitochondrial function. 41 Abnormalities in the electron transport chain, Vascular Medicine 2000; 5: 55-59 which enhance the electrochemical gradient at any step, will result in increased free radical leakage. Thus, the oxidative stress observed in PAD may be an additional reflection of mitochondrial dysfunction. Alternatively, mitochondria are an important target of free radical-induced injury. 41 Work in model systems has demonstrated that exposure to free radicals may lead to direct oxidative injury to critical proteins, with the potential to result in loss of oxidative capacity. 42
Somatic mitochondrial DNA mutations in peripheral arterial disease
Mitochondria contain their own DNA, which encodes for 13 polypeptides critical to the electron transport chain. 21 Unlike nuclear DNA, each cell contains multiple copies of the mitochondrial genome. Mitochondrial DNA is susceptible to injury, and with aging a variety of point and deletion mutations accumulate. 21, 43, 44 The accumulation of these mitochondrial mutations can be accelerated by the presence of chronic diseases, particularly those associated with increased free radical production. 45 Peripheral arterial disease is associated with an increased frequency of a 4977 bp deletion mutation found ubiquitously in human tissues. 24 The high frequency of this mutation in PAD is consistent with mitochondrial changes that occur in this disorder. However, a study of patients with unilateral PAD demonstrated an increased frequency of the 4977 bp deletion in the limb without hemodynamically significant occlusive disease. 24 Across the population of patients with PAD studied, the frequency of the 4977 bp deletion did not predict claudication-limited performance. Finally, the total activity of mitochondrial enzymes encoded within the deleted region was not decreased in PAD. 24 Thus, mitochondrial DNA deletions are not likely to be a primary causative factor in claudication. Instead, mitochondrial DNA injury may reflect the systemic injury that occurs with increased oxidant stress.
The 4977 bp deletion is only one of many potential somatic mutations which can arise in the mitochondrial genome. 44 Subsequent work has demonstrated that a broad spectrum of distinct deletions occur in the mitochondrial genome of patients with PAD (EP Brass et al, unpublished results). Consistent with the interpretation of the 4977 bp deletion observed above, multiple deletions were also found in the unaffected limbs of patients with unilateral disease, and the magnitude of mitochondrial injury could not be related to any functional parameter in a population of PAD patients (EP Brass et al, unpublished results).
Taken together with other observations, the injury to the mitochondrial genome is best interpreted as reflecting the high oxidative stress in the muscle of patients with PAD. As mitochondria are the major source of intracellular free radicals, and as the mitochondrial genome is in close proximity to the mitochondrial inner membrane, the degree of mitochondrial DNA injury may indicate elevated electrochemical gradients within the mitochondrial electron transport chain. Similarly, the presence of increased electrochemical gradient or increased redox potentials within the mitochondria suggest that the mitochondrial electron transport chain is an important site of metabolic dysfunction in the muscle of these patients. Importantly, other diseases associated with abnormal electron transport chain function are associated with both acylcarnitine accumulation 46 and altered mitochondrial respiratory kinetics. 32 For a summary of skeletal muscle metabolic alterations in peripheral arterial disease see Table 1 .
Implications of metabolic abnormalities in PAD
Claudication is associated with substantial physical disability and treatment options are limited. If metabolic abnormalities contribute to the functional disability, then novel therapeutic strategies focusing on metabolic regulation may be efficacious. For example, in heart, drugs that induce the preferential use of glucose versus fat for energy decrease the oxygen requirement per ATP generated. 47, 48 This approach has resulted in enhanced myocardial recovery from acute ischemia in model systems. 47, 48 A number of other potential sites in metabolism which can be perturbed to alter function can be identified, 49 and reported efficacy of propionylcarnitine in improving claudicationlimited exercise performance 50 may further validate this concept.
Exercise rehabilitation may provide both a model for further study of metabolic regulation in peripheral arterial disease and a validation of the importance of alterations in muscle metabolism to the disorder. Exercise rehabilitation improves functional performance in patients with PAD without affecting large vessel hemodynamics. 8, 30 Exercise is a potent regulator of metabolic enzymes in normal individuals. 10, 14 Supporting the concept that exercise rehabilitation modifies muscle metabolism in PAD, the carnitine pool is redistributed from acylcarnitine to carnitine (i.e. decrease in metabolic intermediates and increased complete oxidation) with exercise training. 8, 19 While cause and effect cannot be differentiated in this relationship, the observation supports the concept that therapeutic interventions targeting metabolic regulation may be of benefit in claudication.
As made clear from the discussion above, the specific metabolic abnormality in PAD has yet to be elucidated. While electron transport chain dysfunction is an attractive hypothesis to explain the available observations, further work will be required to prove this hypothesis and elucidate the molecular mechanisms involved.
In summary, there is strong evidence of metabolic abnormalities in the skeletal muscle of patients with peripheral arterial disease. Several lines of evidence support the hypothesis that these metabolic derangements are of functional importance in the pathophysiology of claudication. Therapeutic interventions directed at improving metabolic function in skeletal muscle may be of benefit in patients with claudication.
